MedTrace Logo

Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery

NCT00474773 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2016-04-28

No results posted yet for this study

Summary

This study will evaluate the benefits of continuing celecoxib through six weeks of total knee arthroplasty recovery. This is a randomized, double blind study with a group of approximately 130 primary total knee patients. All patients will receive celecoxib throughout their hospitalization as per current minimally invasive total knee arthroplasty protocol. At the time of hospital discharge, participating patients will be randomly placed on either celecoxib 200mg twice a day or a placebo twice a day.

This study will determine if the continued use of celecoxib for six weeks after total knee arthroplasty hospitalization will further decrease narcotic consumption, improve knee range of motion, improve ambulatory ability, and improve patient satisfaction over patients receiving celecoxib only during the acute hospitalization.

Conditions

  • Pain Management
  • Function
  • Minimally Invasive Total Knee Arthroplasty
  • Celecoxib

Interventions

DRUG

Celecoxib

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Zimmer Biomet

    collaborator INDUSTRY

  • St. Louis Joint Replacement Institute

    lead OTHER

Principal Investigators

  • William C Schroer, MD · St. Louis Joint Replacement Institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00474773 on ClinicalTrials.gov